In a landmark development for cancer care, a new clinical trial has unveiled a paradigm-shifting approach to treating colorectal cancer. The NEOPRISM-CRC study, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), has demonstrated that a short, intensive course of immunotherapy administered prior to surgery can lead to remarkably durable, long-term remission. For a specific subset of patients, this approach has effectively eliminated the disease, with no reported recurrences nearly three years post-treatment.
The findings, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, suggest that moving immunotherapy to the "neoadjuvant" (pre-surgical) setting may offer a superior alternative to the traditional standard of care, which typically involves surgery followed by months of taxing chemotherapy.
The Core Findings: A Shift in Treatment Strategy
The NEOPRISM-CRC trial focused on 32 patients diagnosed with stage two or three colorectal cancer. These patients possessed a specific genetic profile known as MMR-deficient (mismatch repair deficient) or MSI-high (microsatellite instability-high). This genetic signature, found in approximately 10–15% of colorectal cancer cases, indicates that the tumor has difficulty repairing its DNA, making it particularly vulnerable to the immune system’s intervention.
In the trial, patients received a nine-week course of pembrolizumab, an immunotherapy drug designed to "release the brakes" on the immune system, allowing it to identify and attack cancer cells. Unlike conventional chemotherapy, which attacks rapidly dividing cells indiscriminately, pembrolizumab trains the body’s own defense mechanisms to target the tumor.
The results were unprecedented: 59% of patients exhibited a complete pathological response—meaning no detectable cancer was found in the tissue removed during surgery. Even more striking is the long-term data. After a follow-up period of 33 months, zero patients in the trial cohort have experienced a cancer recurrence. By contrast, roughly 25% of patients undergoing the standard "surgery-first" approach followed by chemotherapy typically see their cancer return within three years.
Chronology of a Medical Breakthrough
The success of the NEOPRISM-CRC trial is the result of years of meticulous research and interdisciplinary collaboration.
- Early Diagnosis and Screening: For participants like 73-year-old Christopher Burston, the journey began with routine screening. After blood was detected in a stool sample, a colonoscopy confirmed the presence of a stage three tumor.
- The Enrollment Phase: Upon diagnosis, participants were offered entry into the NEOPRISM trial. The study was conducted across several leading UK hospitals, emphasizing a collaborative effort to standardize a new, more efficient pathway for high-risk patients.
- The Treatment Window (February–May 2023): Patients underwent nine weeks of pembrolizumab immunotherapy. During this period, researchers utilized advanced blood-based monitoring to track the "molecular footprint" of the cancer.
- Surgical Intervention: Following the nine-week course, patients underwent surgery. In many instances, surgeons found that the tumor had significantly shrunk or, as in Burston’s case, "melted away" entirely.
- Post-Treatment Monitoring (2023–2026): For nearly three years, the research team conducted rigorous follow-up, using personalized liquid biopsies to detect any trace of circulating tumor DNA (ctDNA). The absence of relapse throughout this period has confirmed the durability of the initial immune response.
Supporting Data: Why the Treatment Works
The success of the trial lies in the synergy between biology and technology. Researchers identified two primary factors that predict success: the disappearance of tumor DNA from the bloodstream and the specific immune profile of the tumor tissue itself.
The Power of Liquid Biopsies
One of the most innovative aspects of the study was the use of personalized blood tests to track progress. By analyzing the bloodstream for ctDNA, clinicians can determine whether a patient is responding to immunotherapy long before visible tumors shrink on a scan. Yanrong Jiang, the study’s first author, noted that the disappearance of tumor DNA from the blood served as a high-precision indicator of long-term survival. When the ctDNA cleared, the likelihood of remaining cancer-free increased exponentially.
Immune Profiling
Before the first dose of immunotherapy, researchers performed deep immune profiling on tumor tissue samples. This allowed them to understand the "tumor microenvironment"—the ecosystem of cells surrounding the cancer. They found that specific immune signatures could predict which patients would respond most aggressively to pembrolizumab. This provides a blueprint for "precision medicine," where clinicians can tailor the intensity of treatment based on the biological makeup of the individual patient’s cancer.
Official Responses and Clinical Perspectives
The medical community has greeted the results with cautious optimism, viewing them as a potential new "gold standard" for MSI-high colorectal cancers.
Dr. Kai-Keen Shiu, the Chief Investigator from the UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, described the findings as "extremely encouraging."
"Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up strengthens our confidence that pembrolizumab is a safe and highly effective treatment," Dr. Shiu stated. He emphasized that the real breakthrough lies in the ability to predict response. "These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy versus patients at higher risk of disease progression who might require additional interventions."
Professor Marnix Jansen, also of the UCL Cancer Institute, highlighted the biological significance of the study. "These results not only confirm the durability of the responses we saw years ago but also provide crucial insights into the ‘why’ behind immunotherapy’s success in this setting. We are witnessing the immune system creating a long-term memory that continues to guard the patient against recurrence."
Implications for the Future of Cancer Care
The implications of the NEOPRISM-CRC trial extend far beyond the 32 patients involved in the study.
Redefining Standard Care
If these findings are replicated in larger, phase three trials, it could fundamentally change the standard of care for the estimated 2,000–3,000 patients in the UK alone who carry the MSI-high genetic subtype. Shifting the focus from aggressive, systemic chemotherapy to targeted immunotherapy could spare patients from the severe side effects associated with traditional regimens, such as neuropathy, nausea, and immune-suppression.
The Rise of Precision Oncology
The study underscores the necessity of genetic testing at the point of diagnosis. Because this treatment is specifically effective for MMR-deficient or MSI-high tumors, it highlights the importance of molecular diagnostics in determining the treatment path. As these tests become more widely available, the "one-size-fits-all" approach to cancer treatment continues to give way to individualized strategies.
Addressing the Demographic Shift
While bowel cancer remains a disease primarily affecting older adults, the rising incidence among individuals under 50 makes the development of less toxic, highly effective therapies more critical than ever. Providing younger patients with a treatment that allows them to return to their daily routines—without the long-term toxicity of heavy chemotherapy—is a significant advancement in quality-of-life care.
A Patient’s Perspective: The Human Impact
For Christopher Burston, the success of the trial has been life-changing. Reflecting on his experience, he noted the stark difference between the anxiety of a cancer diagnosis and the rapid relief provided by the immunotherapy.
"I saw the images when I had the first colonoscopy and could see it was really quite a substantial lump," Burston recalled. After nine weeks of immunotherapy, his surgeon confirmed that the mass had virtually disappeared. Three years later, Burston is back to his regular life, feeling "very lucky" to focus on the challenges of aging rather than the fight against malignancy. His experience serves as a testament to the clinical success of the trial, turning a daunting prognosis into a manageable, and ultimately curable, condition.
Conclusion
The NEOPRISM-CRC trial represents a significant milestone in the fight against colorectal cancer. By proving that immunotherapy, when used strategically before surgery, can achieve durable, long-term remission, researchers have opened the door to a new era of cancer management. As the medical community looks toward larger trials and the integration of these personalized blood tests into routine practice, the goal remains clear: to replace broad-spectrum, toxic treatments with targeted, immune-based therapies that offer not just survival, but a life free from the specter of recurrence.
